Melanoma is considered one of the most aggressive skin cancers. It spreads and
metastasizes quickly and is intrinsically resistant to most conventional chemotherapeutics …

Non-small-cell lung cancer (NSCLC) is the most common form of primary lung cancer. The
discovery of several oncogenic driver mutations in patients with NSCLC has allowed the …

While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have
changed the treatment landscape for EGFR mutant (L858R and ex19del)-driven non-small …

Purpose The AURA study (ClinicalTrials. gov identifier: NCT01802632) included two cohorts
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …

The Lazarus effect is a rare condition that happens when someone seemingly dead shows
signs of life. The epidermal growth factor receptor (EGFR) represents a target in the fatal …

The epidermal growth factor receptor (EGFR) plays a critical role in the tumorigenesis of
various forms of cancer. Targeting the mutant forms of EGFR has been identified as an …

Adverse event reports submitted to the US Food and Drug Administration (FDA) were
analyzed to map the safety profile of epidermal growth factor receptor-tyrosine kinase …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are treatments
commonly used for lung cancer. The toxicity profile including toxicity incidence, severity, and …

Introduction Amivantamab is a monoclonal bispecific anti-EGFR-MET antibody that is the
first targeted therapy to be approved for non-small cell lung cancer (NSCLC) patients …

Osimertinib is the only Food and Drug Administration‐approved third‐generation epidermal
growth factor receptor (EGFR) tyrosine‐kinase inhibitor (TKI). A meta‐analysis was …